1. Home
  2. AVDL vs WLDN Comparison

AVDL vs WLDN Comparison

Compare AVDL & WLDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • WLDN
  • Stock Information
  • Founded
  • AVDL 2015
  • WLDN 1964
  • Country
  • AVDL Ireland
  • WLDN United States
  • Employees
  • AVDL N/A
  • WLDN N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • WLDN Military/Government/Technical
  • Sector
  • AVDL Health Care
  • WLDN Consumer Discretionary
  • Exchange
  • AVDL Nasdaq
  • WLDN Nasdaq
  • Market Cap
  • AVDL 861.4M
  • WLDN 826.2M
  • IPO Year
  • AVDL 1996
  • WLDN 2006
  • Fundamental
  • Price
  • AVDL $10.04
  • WLDN $76.90
  • Analyst Decision
  • AVDL Strong Buy
  • WLDN Strong Buy
  • Analyst Count
  • AVDL 6
  • WLDN 2
  • Target Price
  • AVDL $18.17
  • WLDN $49.00
  • AVG Volume (30 Days)
  • AVDL 1.6M
  • WLDN 341.1K
  • Earning Date
  • AVDL 08-07-2025
  • WLDN 08-07-2025
  • Dividend Yield
  • AVDL N/A
  • WLDN N/A
  • EPS Growth
  • AVDL N/A
  • WLDN 79.39
  • EPS
  • AVDL N/A
  • WLDN 1.68
  • Revenue
  • AVDL $194,450,000.00
  • WLDN $595,695,000.00
  • Revenue This Year
  • AVDL $56.88
  • WLDN N/A
  • Revenue Next Year
  • AVDL $29.81
  • WLDN $9.94
  • P/E Ratio
  • AVDL N/A
  • WLDN $45.72
  • Revenue Growth
  • AVDL 252.64
  • WLDN 12.40
  • 52 Week Low
  • AVDL $6.38
  • WLDN $30.43
  • 52 Week High
  • AVDL $17.30
  • WLDN $77.03
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 63.41
  • WLDN 88.50
  • Support Level
  • AVDL $8.74
  • WLDN $71.80
  • Resistance Level
  • AVDL $9.56
  • WLDN $75.50
  • Average True Range (ATR)
  • AVDL 0.40
  • WLDN 3.08
  • MACD
  • AVDL 0.08
  • WLDN 0.77
  • Stochastic Oscillator
  • AVDL 98.70
  • WLDN 98.03

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About WLDN Willdan Group Inc.

Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.

Share on Social Networks: